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Crohn’s disease and sarcoidosis, two systemic
granulomatous disorders, on rare occasions
co-exist.
Case report
In 1997, at the age of 42 years, an
African-American woman was diagnosed with
Crohn’s disease. She was appropriately treated
with prednisone and mercaptopurine. In early
2007, she had a normal colonoscopy. In the latter
part of 2007, she developed dyspnoea, retrosternal
discomfort and diffuse joint pains, mainly on the
left side. Other associated symptoms were dry
cough, hoarseness of the voice, diarrhoea and
athralgia, and she was initiated on prednisone
40 mg fora suspected Crohn’s ﬂare. Furtherevalu-
ation in early August 2008 revealed bilateral hilar
adenopathy, diffuse nodular opacities on a chest
X-ray ﬁlm. Admission physical exam revealed
the patient to be afebrile, normotensive and com-
fortable with 95% O2 saturation on room air, with
a regular, unlabored respiratory rate of 18. On pal-
pation, patient was tender on the left superior-
axillary chest wall, with all other systems unre-
markable on assessment. Admission labs are
noted in Table 1. In addition, CRP was 2.1 mg/dL.
High-resolution CT identiﬁed a 5× 4.9 cm soft
tissue mass in the right hilar region, soft tissue
consolidation within the left upper lobe measur-
ing 10× 6.2 mm, nodular opacities, and enlarged
parenchymal nodules. Pulmonary function tests
at baseline are noted in Table 1. Prednisone was
weaned from 40 mg to 15 mg for severe depressive
symptoms.
During the latter part of August, the patient
underwent bronchoscopy and biopsy of the right
hilar lesion with negative cultures and was dis-
charged home with a decrease in her ranitidine
dose, the addition of lansoprazole every
morning, and an increase in prednisone from
15 mg q day to 40 mg q day.
Four months later, in December, the patient was
seen on follow-up for continued complaints of
progressively worsening cough and wheezing
and was admitted. Pulmonary function tests are
noted in Table 2 for comparison. Chest CT
reported an increased obstruction of the right
middle lobe; mercaptopurine was increased to
125 mg. She underwent a bronchoscopy with
washing, removal of granulosis tissue of right
lower lobes, and an initial balloon dilation of the
right main bronchus was performed.
Oneweek later, the patient re-presented for per-
sistently increasing wheezing episodes which led
to a repeat dilatation on an outpatient basis.
Postprocedure follow-up on 2 January 2009 by
CT revealed increased soft tissue in the right
hilar region and persistent obstruction of the
right middle lobe bronchi. Abdominal CTrevealed
an ill-deﬁned hypoattenuating lesion within the
right hepatic lobe and a small rounded density
within the gallbladder. Electrolytes and LFTs
were normal; an elevated ferritin of 1569 was
observed.
Bone marrow biopsy pathology identiﬁed
Epstein-Barr virus (EBV) positive large B cell lym-
phoproliferative disorder, large atypical cells with
positivity for BOB.1, Oct-2, CD79A, and EBER,
and CD20 negative with hypocellular marrow
with normal cytogenetics and no evidence of
clonal lymphoproliferative disorder. The patient
was then referred to haematology/oncology;
meanwhile, her clinical condition worsened, she
developed ‘continuous’ coughing, nausea, vomit-
ing, intermittent sweats, shortness of breath,
weight loss and fatigue. Physical examination
revealed unlabored respirations with room air O2
saturation of 93% and 87% on exertion. An
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1echocardiogram was performed and evaluated as
normal, with an estimated ejection fraction of 61%
and no valvular anomalies. Home oxygen was
initiated; methotrexate and 6-MP were stopped.
At haematology/oncology follow-up in mid-
January 2008, the patient’s respiratory rate was
unlaboured at 18, with 94% saturation on 1.5L
NC. Physical assessment aberrations included
bilateral wheezing. CHOP (cyclophosphamide/
hydroxydaunorubicin/oncovin/prednisone) che-
motherapy, clarithromycin 500 mg bid, and Neu-
lasta are initiated following negative HIV testing
and EBV polymerase chain reaction testing. EBV
DNA detected at 4.7 log copies/mL. AFB culture
demonstrated Mycobacterium gordonae.
Chest X-ray demonstrated an increasing mass-
like opaciﬁcation in the right middle lobewith sur-
rounding perihilar opacities extending to the right
lower lobe. An additional bronchoscopy was per-
formed for persistent cough and right-sided chest
pain. Chemotherapy-induced neutropenia is
resolved with Neulasta administration, as seen in
Table 2.
By mid-February, subsequent HRCT study
revealed a new narrowing of the right lower lobe
bronchus with new central consolidation and
clustered small centrilobular and tree-in-bud
opacities, as well as a new, small right pleural effu-
sion. Due to airway narrowing, the patient under-
went a third outpatient bronchial dilation and
continued with Neulasta and CHOP. Prednisone
is decreased to 7.5 mg q day in between each
21-day cycle of CHOP.
In March, the patient reported worsening short-
ness of breath, coughing and chest pain, and
underwent her fourth bronchial dilation in
three months. Postprocedure vitals demonstrated
improved saturation on room air at 96%. Neutro-
penia is now resolved, normal electrolytes and
LFTs were evaluated and no changes on X-ray
were observed.
An HRCT on 6 April is interpreted with
minimal reduction of right hilar mass and adeno-
pathy, hepatic lobe lesion is now absent on
abdominal/pelvic CT. During physical examin-
ation, the patient complained of ‘airway fullness’.
Wheezes are noted on auscultation in the right
mid-hemi thorax. A ﬂexible bronchoscopy and
repeat tracheal dilation is performed. CHOP #5
and #6 are tolerated with an additional prednisone
decrease to 5 mg every other day.
In May, a repeat PETCT from skull base to mid-
thigh was performed with an increase in right
hilar adenopathy and soft tissue mass of 5.2×
1.8 cm, with consolidative densities suspicious
for a lymphomatous spread, post-obstructive inﬁl-
trates, hyper metabolic lymph nodes in the porta
hepatitis and peripancreatic distributions, with
Table 1
Complete blood counts and coagulabilities 2008 and 2009
26 August
2008
5 December
2008
21 January
2009
28 January
2009
18 March
2009
October
2009
WBC (K/uL) 4.65 7.18 0.32 10.34 3.10 4.34
Hgb (g/dL) 12.4 9.7 9.5 9.2 10.7 13.5
Hct (%) 36.4 28.1 27.9 28.1 32.3 40
Platelets (K/
uL)
500 891 291 578 576 533
PT (s) 14.0 14.2 Not reported Not reported Not reported Not reported
PTT (s) 34 33 Not reported Not reported Not reported Not reported
Table 2
Pulmonary function tests October and December
2008
20 October
2008
December
2008
FVC 3.33
(predicted 88%)
3.12
FEV1 2.54
(predicted 86%)
1.95
DLCO 24.32% 21.73
6-minute
walk test
1989 feet,
nausea,
no dyspnoea
1718 feet
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2multiple sites of hypermetabolism within the
bones, including the left hilum.
Following CHOP #6, vitals remained stable,
breath sounds were now clear to auscultation,
and the patient was saturating 96% on room air.
CBC, BMP and LFTs were all normal; CRP was
reduced to 0.3. A bone marrow biopsy and
bronchoscopy with biopsy were performed. Pre-
dnisone was discontinued.
Bone marrow biopsy shows normocellular
marrow at 50% with trilineage hematopoiesis with
non-caseating granulomas. Peripheral blood smear
showed mild macrocytic normochromic anemia,
neutrophils with a left shift and toxic changes,
absolute lymphopenia and mild thrombocytosis.
On 15 July 2009, the patient presented for a
follow-up with additional complaints of wheezing
and dyspnoea and received an additional broncho-
scopy and sixth bronchial dilation, as well as thor-
acic surgery evaluation for possible resection due
to the frequency of her airway dilations.
Thoracic surgery evaluation in August led to a
right lung resection/middle lobe pneumonectomy
secondary to closure of the right middle and lower
lobe.
Follow-up by haematology/oncology addressed
the patient’s reports of shortness of breath unre-
solved by surgical intervention, with the additional
complaint of a weight loss of 12 lbs. CBC and elec-
trolytes were normal. PET CTof skull base to mid-
thigh in October revealed signiﬁcant progression of
sites of disease within the skeleton, left lung, right
pleural surface, and lymph nodes of the neck,
axilla, and mediastinum, left hilum, perioportal,
retroperitoneal, iliac, and inguinal regions. A left
supraclavicular lymph node is measured at 8 mm,
with an approximate growth of 3 mm from pre-
vious scans. Operative pathology showed benign
lung parenchyma involvement by non-caseating
granulomatous inﬂammation.No morphologic evi-
dence of lymphoma. Mycobacterial and fungal
stains were negative.
On 30 November 2009, the patient was evalu-
ated for possible Remicade use.
Discussion
Sarcoidosis and Crohn’s
The incidence of both sarcoidosis and Crohn’s
disease co-existing in a patient has been suggested
as early as 1947
1 with very few deﬁnite cases
reported in the literature. Fries et al.
2 produced
two cases of both inﬂammatory bowel disease
and sarcoidosis, but were unable to identify a
link between the two conditions. These granulo-
matous disorders are often reported as ‘mimick-
ing’ one another, with up to 10% of patients
affected by sarcoidosis to have alimentary tract
involvement
3 and approximately 40–50% of
patients with inﬂammatory bowel disease
4,5 to
demonstrate respiratory symptoms. Published
hypotheses suggest a genetic link, with CARD15,
a known mutation that contributes to Crohn’s
having no relation to sarcoidosis incidence
6 in
one study with some familial incidence of both
disorders identiﬁed by Willoughby et al.
7 and
Gronhagen-Riska et al.,
8 whereas the autoimmune
response of both diagnoses may include a
common pathogenesis and immune response.
The National Heart, Lung, and Blood Institute uti-
lized Crohn’s disease as a model for the study of
sarcoidosis in 2004, identifying three key simi-
larities between the two: (a) both are chronic gran-
ulomatous inﬂammatory processes that (b) result
in helper T cell type 1 inﬂammation as a primary
immune response and (c) may result from both
environmental and genetic factors that remain
unknown at this time.
9 We recognize the rarity of
our patient presenting with both disease processes
simultaneously.
Lymphoma and Crohn’s
In 2009, The Lancet
10 reported results from the
French CESAME group, indicating a hazard
ratio for LPD of 5.28 for patients with inﬂamma-
tory bowel disease (IBD) receiving thiopurines
for immunosupression, with additional risk for
increased age, male sex and chronic histories of
IBD. Patients primarily presented with non-
Hodgkin lymphomas associated with EBV. The
Pyramid and ENCORE registries are currently
evaluating the risk of developing lymphoma
with anti-TNF medications without thiopurine
use.
Smith et al.
11 published a review article of
association of thiopurines and its use in IBD
and speciﬁc associations of cancers such as lym-
phoma, colorectal cancer, skin cancer and cervical
cancer. Thiopurines are associated with speciﬁc
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3additional risks. In IBD cohorts very few
thiopurine-related malignancies have been
reported. However, studies suggest a relative risk
of 4–5 for lymphoma. This still translates to a
low actual risk (one extra lymphoma in every
300–1400 years of thiopurine treatment).
Jharap et al.
12 published results of an 8-year
cohort study to link discontinuation of thiopurines
with adverse effects. After ﬁve years, only 40% of
patients remained on a thiopurine administration,
primarily related to the high incidence of adverse
effects, with the highest incidence of adverse
effects during the ﬁrst three months of therapy.
Mouse models have been studied to investigate
the causative factors relating chronic inﬂamma-
tory bowel disease to oncologic occurrences. The
study suggests the intestinal epithelial cells are
susceptible to damage due to prolonged antigen
exposure and undergo transcriptional changes
that may lead to malignancy.
Multiple studies, including Lewis et al.
13 and
Askling et al.,
14 have proven no inherent increased
risk of malignancy or lymphoma with the diagno-
sis of IBD alone.
Lymphoma and sarcoidosis
Following Brincker and Wilbek’s data,
15 epide-
miology has established an increased riskof devel-
oping various lymphomas in patients with a
history of sarcoidosis, with the increased risk
quantiﬁed broadly, from 5.5 to 11.5 times the
average patient risk. The highest risk was estab-
lished within the Danish population, inclusive of
more than 2500 patients, with less than 2% of the
case reports later challenged by Brincker himself
in literature.
16 Current literature identiﬁesthe ‘sar-
coidosis lymphoma syndrome’ to include three
key manifestations: sarcoidosis onset 10 years
above average median onset age; a sarcoid
history followed by lymphoid malignancy; and
higher incidence of Hodgkin’s. Further, this vari-
ation in risk allows for a higher risk in patients
with chronic sarcoidosis and those receiving
steroid treatment. Presentation varies and may
complicate diagnosis and delay appropriate treat-
ment. Patients may present with sarcoid or
lymphoma ﬁrst, and vice versa, or may rarely
demonstrate co-existing disease simultaneously.
Chemotherapy, such as steroids, has been
suggested to exacerbate lymphoma development,
which may include non-Hodgkin’s. Further,
malignancy may develop quickly or over many
years. Sites of malignancy may include lungs,
liver, skin and reproductive organs of both male
and female patients.
Conclusion
Extensive literature review failed to demonstrate
linking the co-existence of Crohn’s disease and
sarcoidosis with malignant lymphomas, as we
report in this patient, although theoretically,
these three pathologies are interrelated through
altered immune responses complicated by
current drug therapy. Many clinicians continue
to describe either sarcoid or IBD as ‘mimicking’
the other, so the co-existence may be relatively
under-reported. Additionally, the incidence of
lymphomas in these patients may pre-exist any
treatment, as demonstrated in numerous reports
of the sarcoidosis-lymphoma syndrome. We
anticipate future studies to evaluate LPD in
sarcoid patients not receiving thiopurines and
more genetic research to evaluate linkage of the
disorders on a histopathological and familial
basis. We caution all practitioners in the prescrip-
tion of thiopurines for the treatment of chronic
sarcoidosis and Crohn’s and draw attention to
the August 2009 FDA black box warning.
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